A comparison of the control of asthma provided by Symbicort® Turbuhaler® versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® plus Terbutaline Turbuhaler®
Study identifier:D5890C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort® Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort® Turbuhaler® 320/9 µg/inhalation b.i.d. + one inhalation of Pulmicort® Turbuhaler® 400 µg/dose b.i.d. plus Terbutaline Turbuhaler® 0.4 mg/inhalation as-needed. A 12-month, randomised, double-blind, parallel-group, active controlled, multinational, phase IIIB study in adult patients with asthma, EOS
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Budesonide/Formoterol Turbuhaler, Budesonide Turbuhaler (Pulmicort), Terbutaline Turbuhaler
Sex
All
Actual Enrollment
100
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 May 2005
Primary Completion Date: -
Study Completion Date: 01 Mar 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Symbicort Medical Science Director
AstraZeneca
